IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3322 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded172    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


Year : 2015  |  Volume : 47  |  Issue : 1  |  Page : 80-85

Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure

1 Zydus Research Centre, Sarkhej Bavla, Moraiya, Ahmedabad, India
2 Department of Pharmacology, Torrent Pharmaceuticals Ltd, Research Centre, Village Bhat, Gandhinagar, Ahmedabad, India
3 Department of Pharmacology, C. U. Shah College of Pharmacy and Research, Wadhwan, Gujarat, India

Correspondence Address:
Dr. Hitesh M Soni
Zydus Research Centre, Sarkhej Bavla, Moraiya, Ahmedabad
Login to access the Email id

Source of Support: This study was supported by the management of Zydus Research Centre, Sarkhej-Bavla N.H 8A, Moraiya, Ahmedabad-382213, India, Conflict of Interest: None

DOI: 10.4103/0253-7613.150351

Rights and Permissions

Objectives: The aim was to investigate the nephroprotective effect of combination of aliskiren (ASK), a direct renin inhibitor and pentoxifylline (PTX), inhibitor of tumor necrotic factor-alpha (TNF-alpha), in rat remnant kidney model of chronic kidney disease (CKD). Materials and Methods: Nephrectomized (NPX) rats were treated with ASK (10 mg/kg, p.o.), PTX (100 mg/kg, p.o.), and combination of PTX + ASK once daily for 28 days. We have performed analysis of various renal injury parameters after 4 weeks of treatment. Results: Treatment with PTX, ASK and combination showed significant improvement in urea, creatinine and total protein in plasma when compared with vehicle treated group in NPX rats. ASK and combination of PTX + ASK elicited significant reduction in blood pressure but PTX alone did not produce blood pressure reduction. ASK treatment showed significant elevation in TNF-alpha, whereas PTX and ASK + PTX showed significant reduction in TNF-alpha in plasma. Histopathologically, the extent of the kidney injury was similar in NPX + vehicle and NPX + ASK-treated rats. PTX and ASK + PTX-treated group showed lesser extent of kidney injury. There was good correlation of mRNA expression levels of kidney injury molecule-1 and bradykinin B1 receptor data with histopathological findings in kidney samples and elevated TNF-alpha levels in plasma. Conclusions: We conclude that combination of PTX + ASK may be better therapeutic intervention for nephroprotection in CKD patients.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow